OncoMatch/Clinical Trials/NCT07171528
Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
Is NCT07171528 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for ovarian cancer.
To compare outcomes between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Patients with recurrent ovarian cancer who have received platinum-based chemotherapy (3 or 4 cycles)... The patient's disease must have recurred after platinum-based therapy, and be defined as platinum-sensitive, meaning progression occurred more than 6 months (180 days) after the last administration of platinum-based therapy.
Cannot have received: platinum-based chemotherapy
Patients with recurrent ovarian cancer who are not suitable for platinum-based chemotherapy.
Lab requirements
Blood counts
WBC ≥ 2,500/㎕; Platelet ≥ 100,000/㎕; Hemoglobin ≥ 8 g/dl (after correction in cases of simple iron-deficiency anemia)
Kidney function
Creatinine ≤ 1.5 mg/dL or within 1.5 x ULN; CrCl ≥ 30 mL/min or GFR-EPI ≥ 30 mL/min/1.73m²
Liver function
Total Bilirubin ≤ 1.5 x ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN (≤ 5.0 x ULN if liver metastasis)
Cardiac function
No significant dysfunction; no abnormalities in preoperative pulmonary function tests, ECG, or chest X-rays. For patients with a history of cardiac or pulmonary diseases, collaborative evaluation must confirm surgery is feasible.
Adequate organ function as defined in the table below. 1) Adequate bone marrow function... 2) Adequate renal function... 3) Adequate liver function... 4) No Significant dysfunction in Heart, Lungs, etc.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07171528 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior platinum-based chemotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 19 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages